Brief: Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement

Resverlogix

08/01/2018 13:57

Jan 8 (Reuters) - Resverlogix Corp  RVX.TO : 
    * RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC 
LICENSING 
AGREEMENT 
    * RESVERLOGIX CORP - UNDER TERMS OF AGREEMENT, MEDISON HAS 
EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL 
    * RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, 
ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF 
PRODUCT IN REGION 
    * RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH 
MEDISON 
PHARMA FOR CO'S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN 
ISRAEL AND PALESTINE AUTHORITY 
    * RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL 
REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL 
REGION 
 
Source text for Eikon:  ID:nGNXOLOTRa  
Further company coverage:  RVX.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))